Physician profile
Stephen Andrew Wright
NPI 1467773614
$2,165.70
in general payments reported to CMS, 2019-2025
26 companies · $613 in 2025
The $613 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $137 · 2021: $146 · 2022: $206 · 2023: $231 · 2024: $598 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $536.86 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $375.59 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $184.44 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $136.17 | 2025 | Jornay Pm |
| Welch Allyn | $117.60 | 2021 | |
| Neos Therapeutics, Lp | $109.45 | 2020-2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $96.12 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sobi, INC | $64.92 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.22 | 2020-2022 | |
| Glaxosmithkline, LLC. | $48.31 | 2022-2025 | Bexsero |
| Sanofi-Aventis U.S. LLC | $47.53 | 2025 | |
| Supernus Pharmaceuticals, INC. | $43.01 | 2022-2025 | Qelbree |
| Kaleo, INC. | $40.09 | 2019-2022 | |
| Tris Pharma INC | $37.53 | 2020-2024 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $37.31 | 2025 | Relexxii |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $33.26 | 2025 | Neffy, Grastek, Odactra |
| Genentech USA, INC. | $30.63 | 2019-2020 | |
| Adlon Therapeutics L.P. | $25.82 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $23.48 | 2024 | Daybue |
| Verrica Pharmaceuticals INC. | $20.63 | 2024 | Ycanth |
| Noven Pharmaceuticals, INC. | $20.36 | 2024 | Xelstrym |
| Organon LLC | $17.60 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.45 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $17.07 | 2019 | |
| Noven Therapeutics, LLC | $17.04 | 2024 | Xelstrym |
| Hologic Sales and Service, LLC | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.